193 related articles for article (PubMed ID: 27595792)
1. Functional Properties of Human Cytomegalovirus Hyperimmunoglobulin and Standard Immunoglobulin Preparations.
Germer M; Herbener P; Schüttrumpf J
Ann Transplant; 2016 Sep; 21():558-64. PubMed ID: 27595792
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cytomegalovirus (CMV)-specific neutralization capacity of hyperimmunoglobulin (HIG) versus standard intravenous immunoglobulin (IVIG) preparations: Impact of CMV IgG normalization.
Schampera MS; Schweinzer K; Abele H; Kagan KO; Klein R; Rettig I; Jahn G; Hamprecht K
J Clin Virol; 2017 May; 90():40-45. PubMed ID: 28342316
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins.
Miescher SM; Huber TM; Kühne M; Lieby P; Snydman DR; Vensak JL; Berger M
Vox Sang; 2015 Jul; 109(1):71-8. PubMed ID: 25766313
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations.
Planitzer CB; Saemann MD; Gajek H; Farcet MR; Kreil TR
Transplantation; 2011 Aug; 92(3):267-70. PubMed ID: 21659947
[TBL] [Abstract][Full Text] [Related]
5. Role of pentamer complex-specific and IgG subclass 3 antibodies in HCMV hyperimmunoglobulin and standard intravenous IgG preparations.
Schampera MS; Arellano-Galindo J; Kagan KO; Adler SP; Jahn G; Hamprecht K
Med Microbiol Immunol; 2019 Feb; 208(1):69-80. PubMed ID: 30203132
[TBL] [Abstract][Full Text] [Related]
6. Relative EBV antibody concentrations and cost of standard IVIG and CMV-IVIG for PTLD prophylaxis in solid organ transplant patients.
Ramirez-Avila L; Garner OB; Cherry JD
Pediatr Transplant; 2014 Sep; 18(6):599-601. PubMed ID: 25041939
[TBL] [Abstract][Full Text] [Related]
7. Measurement and assessment of cytomegalovirus of immunoglobulin (Ig) g titer in preparations.
Shibaguchi H; Yamamoto T; Kuroki M; Futagami K
Yakugaku Zasshi; 2010 Jul; 130(7):977-82. PubMed ID: 20606378
[TBL] [Abstract][Full Text] [Related]
8. Functional differences between antiviral activities of sulfonated and intact intravenous immunoglobulin preparations toward varicella-zoster virus and cytomegalovirus.
Yajima M; Shiraki A; Daikoku T; Oyama Y; Yoshida Y; Shiraki K
J Infect Chemother; 2015 Jun; 21(6):427-33. PubMed ID: 25824903
[TBL] [Abstract][Full Text] [Related]
9. Hyperimmune globulin in pregnancy for the prevention of congenital cytomegalovirus disease.
Nigro G
Expert Rev Anti Infect Ther; 2017 Nov; 15(11):977-986. PubMed ID: 29072089
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection.
van Gent R; Metselaar HJ; Kwekkeboom J
Transplant Rev (Orlando); 2017 Apr; 31(2):78-86. PubMed ID: 28131494
[TBL] [Abstract][Full Text] [Related]
11. Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study.
Kagan KO; Enders M; Hoopmann M; Geipel A; Simonini C; Berg C; Gottschalk I; Faschingbauer F; Schneider MO; Ganzenmueller T; Hamprecht K
Ultrasound Obstet Gynecol; 2021 Apr; 57(4):560-567. PubMed ID: 33491819
[TBL] [Abstract][Full Text] [Related]
12. Binding and neutralizing anti-cytomegalovirus activities in immune globulin products.
Wang X; Xu Y; Scott DE; Murata H; Struble EB
Biologicals; 2017 Nov; 50():35-41. PubMed ID: 29029807
[TBL] [Abstract][Full Text] [Related]
13. Interaction of Immunoglobulin with Cytomegalovirus-Infected Cells.
Aiba N; Shiraki A; Yajima M; Oyama Y; Yoshida Y; Ohno A; Yamada H; Takemoto M; Daikoku T; Shiraki K
Viral Immunol; 2017 Sep; 30(7):500-507. PubMed ID: 28598267
[TBL] [Abstract][Full Text] [Related]
14. Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration.
Kagan KO; Enders M; Schampera MS; Baeumel E; Hoopmann M; Geipel A; Berg C; Goelz R; De Catte L; Wallwiener D; Brucker S; Adler SP; Jahn G; Hamprecht K
Ultrasound Obstet Gynecol; 2019 Mar; 53(3):383-389. PubMed ID: 29947159
[TBL] [Abstract][Full Text] [Related]
15. Selection of an intravenous immune globulin for the immunoprophylaxis of cytomegalovirus infections: an in vitro comparison of currently available and previously effective immune globulins.
Chehimi J; Peppard J; Emanuel D
Bone Marrow Transplant; 1987 Dec; 2(4):395-402. PubMed ID: 2844341
[TBL] [Abstract][Full Text] [Related]
16. Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplant recipients: comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV-seronegative patients.
Filipovich AH; Peltier MH; Bechtel MK; Dirksen CL; Strauss SA; Englund JA
Blood; 1992 Nov; 80(10):2656-60. PubMed ID: 1330079
[TBL] [Abstract][Full Text] [Related]
17. The importance of cytomegalovirus-specific antibodies for the prevention of fetal cytomegalovirus infection or disease.
Adler SP; Nigro G
Herpes; 2008 Nov; 15(2):24-7. PubMed ID: 19856544
[TBL] [Abstract][Full Text] [Related]
18. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
19. Prevention and treatment of fetal cytomegalovirus infection with cytomegalovirus hyperimmune globulin: a multicenter study in Madrid.
Blázquez-Gamero D; Galindo Izquierdo A; Del Rosal T; Baquero-Artigao F; Izquierdo Méndez N; Soriano-Ramos M; Rojo Conejo P; González-Tomé MI; García-Burguillo A; Pérez Pérez N; Sánchez V; Ramos-Amador JT; De la Calle M
J Matern Fetal Neonatal Med; 2019 Feb; 32(4):617-625. PubMed ID: 28978246
[TBL] [Abstract][Full Text] [Related]
20. Serum concentrations of immunoglobulins and of antibody isotypes in bone marrow transplant recipients treated with high doses of polyspecific immunoglobulin or with cytomegalovirus hyperimmune globulin.
Gratwohl A; Doran JE; Bachmann P; Scherz R; Späth P; Baumgartner C; Perret B; Berger C; Nissen C; Tichelli A
Bone Marrow Transplant; 1991 Oct; 8(4):275-82. PubMed ID: 1661632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
